Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indomethacin for moderate COVID-19 pneumonia
IRCT20200427047215N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of indomethacin in coronavirus disease 2019 (COVID-19) and pneumonia, sponsored by Isfahan University of Medical Sciences. Primary endpoints: Time to clinical recovery, 14-day readmission rate and 4 more. Started May 2020; status: completed.
02
Drugs
indomethacin
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on IRCT20200427047215N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200427047215N1.